The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration

NCT06994312 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

282

Enrollment

OTHER

Sponsor class

Conditions

Sepsis-induced Coagulopathy (SIC)

Interventions

DRUG: Nafamostat Mesylate
DRUG: sodium citrate

Sponsor

The First Hospital of Jilin University